

REMARKS

Consideration and allowance of the above-referenced application are respectfully requested.


The present document is responsive to the restriction requirement contained in the Office Action of June 21, 2005, issued in connection with the patent application identified above. In particular, as noted above, Applicants respectfully elect Group I (i.e., claims 1-5), as well as SEQ ID NO: 25 and SEQ ID NO:26, with traverse. Further, Applicants reserve the right to file divisional applications in the future in connection with the non-elected groups.

Additionally, claims 1 and 2 have been amended to delete the non-elected amino acid and nucleotide sequences, respectively, and contain no subject matter beyond that present in the original application as filed.

Should the Examiner have any questions concerning this matter, she is respectfully requested to contact the undersigned at the telephone number listed below.

ABBOTT LABORATORIES
Customer No.: 23492
Telephone: (847) 935-1729
Facsimile: (847) 938-2623

Respectfully submitted,
Mukerji, et al.


Cheryl L. Becker
Registration No. 35,441
Attorney for Applicants